Overview

Ivosidenib is a selective inhibitor of mutant IDH1, the enzyme that drives production of the oncometabolite 2-hydroxyglutarate in IDH1-mutated cancers. In acute myeloid leukemia (AML), its most validated use is not as a single agent but in combination with azacitidine, a hypomethylating agent. This combination strategy targets newly diagnosed AML carrying an IDH1 R132 mutation in patients who cannot tolerate intensive induction chemotherapy, a population with historically poor outcomes.

The AGILE Trial Basis

The clinical foundation for the combination is the AGILE study (ClinicalTrials.gov NCT03173248), a phase 3, randomized, placebo-controlled trial comparing ivosidenib plus azacitidine with azacitidine plus placebo. Enrolled patients had previously untreated AML with an IDH1 mutation and were not candidates for intensive chemotherapy. The trial demonstrated clinical benefit supporting regulatory approval of ivosidenib in combination with azacitidine for newly diagnosed AML with an IDH1 R132 mutation in this ineligible-for-intensive-therapy population, establishing the combination as a standard frontline option.

Why the Combination Makes Sense

Azacitidine lays epigenetic and differentiation pressure on leukemic blasts, while ivosidenib interrupts the mutant IDH1–2-hydroxyglutarate axis that blocks normal myeloid maturation. The two mechanisms are complementary: inhibiting mutant IDH1 can permit differentiation of previously arrested progenitors, and the hypomethylating backbone broadens the antileukemic effect. Using them together from diagnosis targets both the differentiation block and the proliferation signal simultaneously.

The Diagnostic Prerequisite

A central feature of this strategy is that it is biomarker-defined. Combination therapy is appropriate only after an IDH1 R132 mutation is confirmed by validated testing, because patients without the mutation are not expected to benefit from IDH1 inhibition. This makes companion diagnostics and timely mutation reporting integral to the combination workflow rather than optional add-ons.

FAQ

Q: In which AML population is ivosidenib combined with azacitidine? A: Newly diagnosed AML with a confirmed IDH1 R132 mutation in patients who are not eligible for intensive induction chemotherapy, per the AGILE trial population.

Q: What was the AGILE trial design? A: A phase 3, randomized, placebo-controlled study of ivosidenib plus azacitidine versus azacitidine plus placebo in previously untreated IDH1-mutated AML unsuitable for intensive chemo (NCT03173248).

Q: Can the combination be used without mutation testing? A: No. IDH1 R132 confirmation is required, since ivosidenib targets the mutant enzyme and non-mutated disease is not expected to respond.

Q: What strength is referenced for this product? A: The 250 mg tablet strength supplied in a 60-tablet pack is the configuration referenced for this product.